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ABSTRACT 
Objective: To develop a novel colon targeted tablet formulation using natural polysaccharides such as kondagogu gum and ghatti gum as carriers 
and diltiazem hydrochloride as a model drug.  
Methods: The polymer-drug tablets were prepared by wet granulation technique, coated with two layers viz., inulin as an inner coat followed by 
shellac as outer coat and evaluated for properties such as average weight, hardness and coat thickness. In vitro release studies of prepared tablets 
were carried out for 2 h in pH 1.2 HCl buffer, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic fluid (SCF) in order to mimic the conditions 
from mouth to colon.  
Results: Percentage weight variation, percent friability and content of active ingredient for all the formulations were found to be well within United 
States Pharmacopoeia (USP) limits. Out of both the polymers, the tablets prepared with ghatti gum showed the maximum hardness of 7.1 kg/cm2. 
The FTIR spectra of pure diltiazem HCl and the formulation KF3 were found to be identical. From the DSC, it was evident that the melting point peak 
of diltiazem HCl and formulation KF3 were observed at 217.16 and 218.34 °C respectively. In vitro studies revealed that the tablets coated with 
shellac (2.5% w/w), prevented the drug release in stomach environment and inulin coated tablets (4% w/w) have limited the drug release in the 
small intestinal environment. The data obtained from in vitro drug release studies were fit into Peppas model and in all the cases the value of A was 
found to be more than 2, i.e., drug release by a combination of both diffusion and erosion-controlled drug release.  
Conclusion: The study revealed that polysaccharides as carriers and inulin and shellac as a coating material can be used effectively for colon 
targeting of drugs for treating local as well as systemic disorders. 
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Oral administration of drugs is one of the most convenient routes 
and is associated with superior patient compliance compared to 
other routes of drug administration [1]. Targeting drug to a specific 
area not only increases the therapeutic efficacy of drugs but also it 
aims to decrease the toxicity associated with drugs to allow lower 
doses to be used in therapy [2]. In recent studies, colon targeted 
drug delivery systems are gaining importance to treat local 
pathologies of the colon and also for the systemic delivery of protein 
and peptide drugs [3].  
Drug targeting to the colon is also useful when a delay in drug 
absorption is desired from a therapeutic point of view, such as 
treatment of diseases that have peak symptoms in the early morning 
like nocturnal asthma, angina or arthritis [4, 5]. CODESTM is a unique 
technology that was developed by utilizing a unique mechanism 
involving lactulose, which acts as a trigger form site-specific drug 
release in the colon [6, 7]. The system consists of a traditional tablet 
core containing lactulose, which is coated with and soluble acid 
material like Eudragit E [8, 9].  
Kondagugu gum (KG) is the dried exudates obtained from tree 
Cochlospermum gossypium belonging to the family Bixaceae [10, 11]. 
It is used as a wound dressing sponge [12], food additive [13], buccal 
disc [14], the carrier in preparing floating drug delivery system [15] 
and a polyelectrolyte complex in combination with chitosan [16]. 
Gum ghatti is a complex non-starch polysaccharide obtained as 
amorphous translucent mucilage from wounds in the bark of 
Anogeissus latifolia [17]. Ghatti gum has also been used for preparing 
matrix tablets for domperidone [18], a floating drug delivery system 
[19] and also as an emulsifying agent [20]. 
Inulin is a polysaccharide obtained from plants such as onion, garlic, 
chicory, artichoke, etc. Only enzymes secreted by the microflora of 
colon degrade inulin [21]. Shellac is a resinous secretion of the insect 
Laccifer lacca and it is used as an enteric coat to prevent the drug 
release from the tablet in the stomach [22]. The drug selected for the 
present study is diltiazem hydrochloride, a calcium channel blocker, 
which is used in the treatment of early morning angina [23]. The 
present work aims to develop a novel colon targeted tablet 
formulation using kondagogu gum and ghatti gum as carriers and 
diltiazem hydrochloride as a model drug.  
MATERIALS AND METHODS 
Materials  
Diltiazem HCl was obtained as a gift sample from M/s Divis 
Laboratories, Hyderabad, India. Diltiazem HCl is a white, odorless, 
crystalline powder freely soluble in water and methanol. Kondagogu 
gum and ghatti gum were purchased from the Girijan Co-operative 
Society, Govt. of Andhra Pradesh, Hyderabad. Inulin and shellac 
were procured from M/s Loba Chemie, Mumbai, India. All other 
ingredients used were of analytical grade. 
Purification of gums 
First the extraneous foreign matter like bark etc was separated from 
both kondagogu gum and ghatti gum, and then powdered using a 
mixer grinder and passed through sieve #80. The powdered gum was 
dispersed in distilled water to get a 1% solution, kept in a sonicator for 
10 min until it was clear and then added to an equimolar mixture of 
acetone and ethanol (2:1 v/v) to give precipitation of gum. The 
precipitated polymer was kept in an oven at 40 °C for drying, 
powdered and evaluated for general characteristic properties [18].  
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Preparation of diltiazem HCl-polymer matrix tablets 
Preliminary studies had demonstrated that directly compressed 
kondagogu gum and ghatti gum formulations lacked the required 
mechanical strength. Hence all the core tablets were prepared by wet 
granulation technique. Accurately weighed quantities of the drug, 
polymer (kondagogu gum/ghatti gum) and binder (PVP K-30, 3% w/w) 
were physically blended in a mortar and pestle. The required quantity of 
the ethanol (solvent) was added and the resultant mixture was mixed 
thoroughly to form a dough mass suitable for the preparation of 
granules. The dough mass was then passed through sieve # 22 to form 
granules which were dried in an oven at 60 °C. The granules were mixed 
with required quantities of lactose (diluent) and lubricant (magnesium 
stearate, 2% w/w) and were compressed to form tablets in a 10-station 
rotary tablet machine (Rimek, Mumbai, India) at 10 RPM and using 9 
mm round concave punches at optimum pressure [4, 15]. Three 
formulations of 300 tablets each were prepared with different amount of 
kondagogu gum viz., 25, 50 and 75% w/w of the tablet (KF1, KF2 and 
KF3) and ghatti gum-based matrix tablets (GF1, GF2 and GF3 code for 
25, 50 and 75% w/w of ghatti gum respectively) as shown in table 1. The 
prepared core tablets were evaluated for tablet properties such as 
hardness, thickness, weight variation, percent friability and drug content. 
Drug content studies were carried out to evaluate the amount of drug 
present in the prepared tablet. 
 
Table 1: Composition of diltiazem HCl colon targeted tablets 
Ingredients  Formulation code and weight in mg 
KF1 KF2 KF3 GF1 GF2 GF3 
Diltiazem HCl 60 60 60 60 60 60 
Kondagogu gum 75 150 225 -- -- -- 
Ghatti gum -- -- -- 75 150 225 
PVP K-30 9 9 9 9 9 9 
Magnesium Stearate 6 6 6 6 6 6 
Directly compressible lactose 150 75 -- 150 75 -- 
Total weight of tablet (mg) 300 300 300 300 300 300 
 
Coating of the prepared tablets  
For the primary coat, a solution of inulin (10% w/v) in hot water (80 
°C) was used to get the desired weight gain (4% w/w) on the tablets. 
Triethyl citrate (1.5% w/w of inulin) and polyethylene glycol (PEG 
6,000, 4% w/w of inulin) were used as plasticizers and magnesium 
stearate (12% w/w of inulin) was added to reduce the tackiness of 
the tablets. For the secondary coat, which is enteric in nature, a 
solution of shellac (20% w/v) in ethanol was used to get the desired 
weight gain (2.5% w/w) over the tablets. PEG 6000 (4% w/w of 
shellac) was used as a plasticizer. Both the coating solutions were 
passed through a 0.3 mm sieve prior to coating. The prepared matrix 
tablets were coated with the inulin solution by spray coating. 
Coating of the tablets has been carried out in a conventional coating 
pan (Ram Scientific Suppliers, Bangalore, India) at an inlet 
temperature of 55 °C, pan rotation speed of 15 RPM, spray pressure 
of 4 kg/cm2 and a spray rate of 10 ml/min. A pilot type spray gun 
(Bullows 630) fitted with a 1 mm atomizing nozzle was used to 
spray the solution [4, 8, 9]. The coated tablets were subsequently 
evaluated for hardness and drug content. 
UV/Visible spectroscopy 
The wavelength of maximum absorbance (λmax) of diltiazem 
hydrochloride drug was determined by scanning a known concentration 
of sample solution in the wavelength region 200–400 nm by using 
Shimadzu 1601 UV/Visible spectrophotometer [24]. The λmax was found 
to be 237 nm and this wavelength was used for further studies.  
FTIR Spectrophotometry  
In order to evaluate the integrity and compatibility of diltiazem with 
the carrier polymers in the polymer-drug matrix formulations, IR 
spectra of the drug and its optimized formulation were obtained by 
FTIR spectrophotometer (Perkin Elmer-1000, Japan), using a 
potassium bromide pellet method [25]. 
Differential scanning calorimetry (DSC) 
DSC thermograms were recorded for pure diltiazem HCl drug and 
the optimized formulation. Accurately weighed samples were placed 
on aluminum plates, sealed with aluminum lids and heated at a 
constant rate of 5 °/min over a temperature range of 0–400 °C [15]. 
All dynamic DSC studies were carried out using a DuPont thermal 
analyzer with 2010 DSC module. 
Scanning electron microscopy (SEM)  
To evaluate the uniformity of coat on the polymer-drug blend (core) 
tablet and to examine the coat morphology, scanning electron 
microscopy (Joel-LV-5600, USA) studies were performed [26]. 
In vitro dissolution studies 
Dissolution testing of colon delivery systems with the conventional 
basket method has usually been conducted in different buffers for 
different periods of time to simulate the GI tract pH and transit time 
that the colon-specific delivery systems might encounter in vivo. 
Dissolution studies were carried out using USP XXII dissolution 
apparatus, basket type at 100 RPM and 37±1 °C. In vitro drug 
delivery studies were carried out for 2 h in 900 ml of 1.2 pH (HCl 
buffer), 3 h in 900 ml of 7.4 pH (phosphate buffer) and for 6 h in 100 
ml of SCF [27, 28]. The samples were withdrawn at regular intervals 
and analysed spectrophotometrically at 237 nm for drug release. 
Preparation of simulated colonic fluid (SCF)  
To evaluate the performance of colon-specific delivery systems 
triggered by colon specific bacteria, animal cecal contents of rats 
have been utilized as an alternative dissolution medium. Because of 
the similarity of human and rodent colonic microflora, 
predominantly comprising Bifidobacteria, Bacteroides and 
Lactobacillus, rat cecal contents were used for dissolution studies. 
4% w/v of rat cecal contents in pH 7 saline phosphate buffer, 
incubated for 24 h was used as SCF [4, 29]. Incubation of the 
prepared solution was carried out in order to increase the enzyme 
concentration. This is done in order to simulate the conditions of 
human colon wherein a large amount of cecal contents would be 
present. As the bacteria present in cecal contents are predominantly 
anaerobic, all the processes were done by keeping the solution 
bubbled with carbon dioxide. Dissolution studies were carried out in 
both incubated and unincubated SCF to check the effect of the 
enzyme’s action over drug release. 
Peppas model fitting 
Koresmeyer-Peppas model is one of the mathematical expression to 
evaluate the mechanism of drug delivery [30]. The Koresmeyer-
Peppas equation is as follows;  
Mt/M∞ = 1-A (exp-kt) ……. (1) 
log (1-Mt/M∞) = log A–kt/2.303 ……. (2) 
Where, Mt/M∞ is the fractional amount of drug released and t is 
the time in h. In this study, the release constant, k and constant, A 
were calculated from the slopes and intercepts of the plot of In (1-
Mt/M∞) versus time t respectively where, Mt is the amount of drug 
release at time t; M∞ is the amount of drug release after infinite 
time; k is a release rate constant incorporating structural and 
geometric characteristics of the tablet, and A is the diffusional 
exponent indicative of the mechanism of drug release. 
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Stability studies  
Stability studies for the optimized formulation of matrix tablets 
was carried out to determine the effect of formulation additives 
on the stability of the drug in the final formulation and also to 
determine the physical stability. The optimized formulation was 
subjected to stability studies according to ICH guidelines by 
storing at 25±2 °C/60±5 % RH and 30±2 °C/65±5 % RH for 12 
mo, and 40±2 °C/75±5 % RH for 6 mo (Thermolab, Mumbai, 
India). The samples were analyzed and checked for changes in 
physical appearance and drug content at regular intervals [15, 
17]. 
RESULTS AND DISCUSSION 
The prepared core tablets were showing an average diameter of 9 mm. 
Percentage weight variation, percent friability, and content of active 
ingredient for all the formulations were found to be well within United 
States Pharmacopoeia (USP) limits. The polymer coated tablets were 
evaluated for hardness and drug content. The prepared tablets were 
evaluated for properties such as hardness (Inweka hardness tester, 
Ahmedabad, India), thickness (Mitotoya screw gauge, Japan), weight 
variation (Shimadzu AW 120, Japan), percent friability (Electrolab EF-2 
friabilator, Mumbai, India) and drug content (Shimadzu 1702 UV/Visible 
spectrophotometer, Japan). The data obtained for coated and uncoated 
tablets is given in table 2. 
  
Table 2: Evaluation data obtained for prepared tablets 
Formulation 
code 
Uncoated tablets Coated tablets 














KF1 301±3.2 5.02±0.11 5.7±0.52 0.42±0.12 100.2±2.4 5.8±0.41 99.8±1.8 
KF2 302±2.9 5.01±0.10 6.3±0.38 0.38±0.11 101.8±2.6 6.5±0.51 101.1±2.5 
KF3 299±3.1 4.99±0.12 6.6±0.45 0.31±0.11 100.3±3.1 6.8±0.39 99.5±2.3 
GF1 299±2.4 5.01±0.11 5.9±0.73 0.39±0.13 98.7±1.8 6.2±0.46 98.2±2.6 
GF2 301±3.1 4.99±0.12 6.9±0.82 0.34±0.11 100.5±2.2 7.1±0.54 99.7±1.4 
GF3 301±2.9 4.98±0.13 7.1±0.46 0.28±0.12 101.4±3.2 7.4±0.84 100.1±2.9 
*mean±SD, n = 3 
 
From the table, it is clear that the hardness of the core tablets 
increased as the amount of polymer concentration in the tablet 
increased. Formulations containing 75% w/w of the gums (KF3 and 
GF3) showed the maximum hardness among the three ratios 
selected (25%, 50% and 75%). Out of both the polymers, the tablets 
prepared with ghatti gum showed the maximum hardness of 7.1 
kg/cm2. The estimated drug content before and after the coating of 
the tablets is given in table 2. From the table it was noticed that, the 
percentage of drug content lies in the range 98.7–101.4 and 98.2–
101.1 for before and after coating operation of the tablets 
respectively. This result clearly indicates that a slight reduction in 
drug content occurred during the coating operation and this is 
expected. 
The FTIR spectra of pure diltiazem HCl and the formulation KF3 
were found to be identical as shown in fig. 1. The characteristic IR 
absorption peaks of diltiazem at 2966 (aliphatic C–H stretch), 2837 
(O–CH3 stretch), 2393 (amine HCl), 1679 (lactam C=O stretch), 839 
(o-substituted aromatic C–H out of plane deformation) and 781 cm-1 




Fig. 1: FTIR chromatogram for pure diltiazem (peak A) and formulation KF3 (peak B) 
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The FTIR spectra obtained indicated that no chemical interaction 
occurred between the drug, diltiazem, polymers and the excipients 
used in formulating the tablet. But, a slight shift in absorption peak 
position was noticed which indicated that physical interaction might 
have occurred between the drug and the polymer/excipients used. 
From the DSC data obtained (fig. 2), it was evident that the melting 
point of diltiazem HCl has not changed after placing the tablets for 
stability studies (peaks at 217.16 and 218.34 °C for pure drug and 
formulation KF3 respectively). Hence, it may be inferred that there 
was no interaction between diltiazem and polymers used. 
  
 
Fig. 2: DSC chromatogram for pure diltiazem HCl (peak A) and formulation KF3 (peak B) 
 
From DSC results it can be concluded that the drug maintained its 
chemical identity throughout the process. The obtained SEM 




Fig. 3: SEM microphotograph of tablet surface after inulin (A) and shellac (B) coating 
 
From the fig. it is evident that the shellac coating was smooth when 
compared to inulin coat. This can be attributed to the high molecular 
weight and complex structure of inulin. 
The plot of cumulative drug release as a function of time is 
shown in fig. 4 and from the fig. it is clear that all the 
formulations did not show any drug release in pH 1.2 buffer 
indicating that shellac has prevented the drug release in stomach 
environment. In vitro studies revealed that the formulations 
containing 25 % of kondagogu gum and ghatti gum (KF1 and GF1 
respectively) could not show sustained release whereas, the 
formulations KF2 and GF2 (50% w/w of kondagogu gum and 
ghatti gum) showed sustained drug release from the coated 
tablets over a period of time. Kondagogu and ghatti gum 
formulations containing 25 % w/w of the tablet (KF1 and GF1) 
released entire drug within 8 h of dissolution period. On the 
other hand, tablets containing 50% w/w of Kondagogu gum and 
ghatti gum (KF2 and GF2) showed about 47 and 51% of drug 
release at the end of 6 h indicating that the formulation did not 
with hold the drug before it reached the target site. 
Bose et al. 




Fig. 4: In vitro drug release profile for the prepared tablet formulations (Data represents mean±SEM (n=3) 
 
The formulations KF3 and GF3 were found to show a low amount of 
about 19 and 22% of the drug in pH 7.4 phosphate buffer (small 
intestinal environment) and released the remaining amount of drug 
in the colonic environment. Drug delivery studies revealed that the 
tablets coated with shellac (2.5% w/w), prevented the drug release 
in stomach environment and inulin coated tablets (4% w/w) have 
limited the drug release in the small intestinal environment. On 
reaching the colonic environment, the inulin coat gets biodegraded 
in the bacteriological media and the drug present in the core gets 
exposed to the bacteriological solution. The bacteria present in the 
solution breakdown the polysaccharide units and the drug gets 
released. 
At the end of 11 h of dissolution, 80% of the drug was released from 
the polymer-drug blend tablet. This is because of the multiplication 
of bacteria present in the cecal content, which got multiplied during 
the incubation period and the enzymes secreted by the bacteria have 
enhanced the rate of biodegradation of the coated and matrix 
polysaccharides used. Hence, for all the drug release studies 
incubated SCF was used. 
The data obtained from in vitro drug release studies were fit into the 
Peppas model. From the plot of log Mt/M∞ versus t, the parameters such 
as release constant (k), constant (A) and the regression coefficient (R2) 
were calculated and the obtained values are shown in table 3. 
In all the cases the value of A was found to be more than 2. This result 
indicates that the release of drug from the polymer matrix formulations 
was found to be super case-II transport, i.e., drug release by a 
combination of both diffusion and erosion-controlled drug release. From 
the table it was concluded that formulation KF3 with R2 value of 0.9941 
is the optimized formulation for colon targeted delivery. 
The optimized formulation KF3 was subjected for stability studies. 
Stability studies of the drug formulations are performed to ascertain 
whether the drug undergoes any degradation during its shelf life. 
The data obtained from the stability studies are tabulated in table 4. 
  
Table 3: Data obtained from Peppas model fitting for the formulations 
Parameters KF1 KF2 KF3 GF1 GF2 GF3 
Constant (A) 2.324 2.257 2.362 2.214 2.278 2.307 
Regression coefficient (R2) 0.9867 0.9836 0.9941 0.9721 0.9875 0.9896 
 
Table 4: Stability study data of optimized formulation KF3 
Stability condition Sampling interval (Months) Formulation KF3 
Physical appearance % Drug content 
 
25±2 ˚C/ 
60±5 % RH 
0 No change 99.5±2.3 
3 No change 99.2±2.8 
6 No change 98.8±2.7 
12 No change 98.5±2.6 
30±2 ˚C/ 
65±5 % RH 
0 No change 99.5±2.9 
3 No change 99.4±2.3 
6 No change 98.9±2.6 
12 No change 98.7±2.8 
 
40±2 ˚C/ 
75±5 % RH 
0 No change 99.5±2.4 
3 No change 99.3±2.1 
6 No change 98.6±2.5 
*Standard deviation n=3, from the stability study data, it was clear that the drug was stable in the optimized formulation for the study period.  
 
CONCLUSION 
From the present study, it can be concluded that kondagogu gum 
and ghatti gum, which are natural and biodegradable polymers can 
be employed for use as carriers in developing colon targeted drug 
delivery systems. However, kondagogu gum was found to be 
superior to ghatti gum as a carrier for colon targeting.  
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